HIV remains highly prevalent in sub-Saharan Africa with nearly 1:5 adults aged 15-49 years infected in South Africa (SA). Although SA also has the largest antiretroviral (ART) program globally, with >2 million PLWH accessing care, a significant proportion of individuals remain ART naïve. The result is two sub-populations- one at high risk of the effects of immunocompromise, and the other living with chronic HIV and the emergent problems of aging. Despite early reports that clade C was less neuro-virulent, regional data suggest that HIV tat variants are not neuro-protective. The presence of neurocognitive impairment is likely impacted by education, early life adversity, neurologic and psychiatric co-morbidity and delays in entering care. ART neurotoxicity is not well understood at a population level, but the up-coming programmatic switch to first-line dolutegravir from efavirenz in SA may help. HAND is not routinely recognized or diagnosed in routine clinical care. Screening tools such as the IHDS and CAT-rapid have been validated in South Africa, with comparable sensitivity and specificity to the USA, but few providers are comfortable using them. Other tools, such as the Community Screening Instrument for Dementia have been used widely across multiple resource-limited settings, but in older persons. Other challenges to diagnosis include the risk of over-diagnosis, especially of mild HAND, the assessment of functional impairment, and the detection of co-morbidities. There are no effective adjuvant treatments for HAND. Effective viral control is key, with CSF escape likely very uncommon. Thoughtful psycho-education, treatment support, and possibly patient-tailored medication management and problem-solving strategies may help. HIV infection in persons >60 years is common and will become a growing problem. Neurodegenerative disorders, including Alzheimer’s and Vascular dementia, are prevalent in older South Africans. The contribution of HIV infection to morbidity is not well understood, even in well-resourced settings. A life-span, patient-centered approach may afford the best outcomes: improving early education, the effects of poverty, managing mid-life risk factors, early HIV diagnosis, and effective ART will probably reduce the disease burden substantially. If one is honest, current Alzheimer treatments are only modestly effective and unaffordable in low-resource settings. We will have to look for cheaper, disease-modifying treatments.